Market Access Is money the only metric that really matters in UK’s VPAG? I... The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.
News UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.
News NHS set for £30bn boost in spending review The NHS is said to be in line for a £30bn increase to its budget in the upcoming spending review, but some are concerned it will not be enough.
News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.
News NICE relents and backs drug for IgAN from CSL Vifor Thousands of people living with rare kidney disease IgAN in the UK will soon be able to access a new oral treatment from CSL Vifor.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.